Clinical Trial Update: A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating various treatments for endometrial cancer with serous histology or p53 abnormalities has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Snippet

Sponsor: University Health Network, Toronto | Conditions: Endometrial Carcinoma, P53 Mutation | Phase 2, Phase 3 | Status: TERMINATED